Acorda, Watson partner to introduce generic zanaflex capsules - Pharmaceutical Business Review
Acorda, Watson partner to introduce generic zanaflex capsulesPharmaceutical Business ReviewAcorda Therapeutics and Watson Pharma, a subsidiary of Watson Pharmaceuticals, have collaborated to introduce tizanidine hydrochloride capsules, an authorized generic version of zanaflex capsules (tizanidine hydrochloride).
Short Term Swing Trades 2 Week Report Card, With Deeper Analysis - Seeking Alpha
Short Term Swing Trades 2 Week Report Card, With Deeper AnalysisSeeking AlphaYesterday, on 2/6/11, Acorda announced that the company has partnered with Watson Pharma (WPI), to introduce tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES.
Acorda Therapeutics to Present at 14th Annual BIO CEO & Investor Conference - EON: Enhanced Online News (press release)
Acorda Therapeutics to Present at 14th Annual BIO CEO & Investor ConferenceEON: Enhanced Online News (press release)The Company also markets ZANAFLEX CAPSULES ® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity.
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment ... - BioMedReports (subscription)
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment .
3 arrested in York County drug busts - The Herald | HeraldOnline.com
3 arrested in York County drug bustsThe Herald | HeraldOnline.